These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 23857704)

  • 1. Tumour diploidy and survival in breast cancer patients with BRCA2 mutations.
    Tryggvadottir L; Olafsdottir EJ; Olafsdottir GH; Sigurdsson H; Johannsson OT; Bjorgvinsson E; Alexiusdottir K; Stefansson OA; Agnarsson BA; Narod SA; Eyfjord JE; Jonasson JG
    Breast Cancer Res Treat; 2013 Jul; 140(2):375-84. PubMed ID: 23857704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer progression and survival in BRCA2 mutation carriers.
    Tryggvadóttir L; Vidarsdóttir L; Thorgeirsson T; Jonasson JG; Olafsdóttir EJ; Olafsdóttir GH; Rafnar T; Thorlacius S; Jonsson E; Eyfjord JE; Tulinius H
    J Natl Cancer Inst; 2007 Jun; 99(12):929-35. PubMed ID: 17565157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000.
    Tryggvadottir L; Sigvaldason H; Olafsdottir GH; Jonasson JG; Jonsson T; Tulinius H; Eyfjörd JE
    J Natl Cancer Inst; 2006 Jan; 98(2):116-22. PubMed ID: 16418514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA2 mutation carriers, reproductive factors and breast cancer risk.
    Tryggvadottir L; Olafsdottir EJ; Gudlaugsdottir S; Thorlacius S; Jonasson JG; Tulinius H; Eyfjord JE
    Breast Cancer Res; 2003; 5(5):R121-8. PubMed ID: 12927042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
    Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
    J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer.
    Huzarski T; Byrski T; Gronwald J; Górski B; Domagala P; Cybulski C; Oszurek O; Szwiec M; Gugala K; Stawicka M; Morawiec Z; Mierzwa T; Janiszewska H; Kilar E; Marczyk E; Kozak-Klonowska B; Siolek M; Surdyka D; Wisniowski R; Posmyk M; Sun P; Lubinski J; Narod SA
    J Clin Oncol; 2013 Sep; 31(26):3191-6. PubMed ID: 23940229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families.
    Thorne H; Willems AJ; Niedermayr E; Hoh IM; Li J; Clouston D; Mitchell G; Fox S; Hopper JL; ; Bolton D
    Cancer Prev Res (Phila); 2011 Jul; 4(7):1002-10. PubMed ID: 21733824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
    Rennert G; Bisland-Naggan S; Barnett-Griness O; Bar-Joseph N; Zhang S; Rennert HS; Narod SA
    N Engl J Med; 2007 Jul; 357(2):115-23. PubMed ID: 17625123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hereditary breast/ovarian cancer: clinicopathological characteristics and survival of BRCA2 positive and negative cases.
    Syamala V; Syamala VS; Sreeja L; Raveendran PB; Vijayalekshmi RV; Sheeja VR; Santhi S; Kuttan R; Abraham EK; Ankathil R
    J Exp Ther Oncol; 2008; 7(3):227-36. PubMed ID: 19066131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers.
    Jonasson JG; Stefansson OA; Johannsson OT; Sigurdsson H; Agnarsson BA; Olafsdottir GH; Alexiusdottir KK; Stefansdottir H; Munoz Mitev R; Olafsdottir K; Olafsdottir K; Arason A; Stefansdottir V; Olafsdottir EJ; Barkardottir RB; Eyfjord JE; Narod SA; Tryggvadóttir L
    Br J Cancer; 2016 Sep; 115(7):776-83. PubMed ID: 27537391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of BRCA2 polymorphism at codon 784 (Met/Val) with breast cancer risk and prognosis.
    Ishitobi M; Miyoshi Y; Ando A; Hasegawa S; Egawa C; Tamaki Y; Monden M; Noguchi S
    Clin Cancer Res; 2003 Apr; 9(4):1376-80. PubMed ID: 12684407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
    Bernholtz S; Laitman Y; Kaufman B; Shimon-Paluch S; Friedman E
    Breast Cancer Res Treat; 2012 Apr; 132(2):669-73. PubMed ID: 22113258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
    Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
    Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
    Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
    Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
    Arnes JB; Brunet JS; Stefansson I; Bégin LR; Wong N; Chappuis PO; Akslen LA; Foulkes WD
    Clin Cancer Res; 2005 Jun; 11(11):4003-11. PubMed ID: 15930334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data.
    Goffin JR; Chappuis PO; Bégin LR; Wong N; Brunet JS; Hamel N; Paradis AJ; Boyd J; Foulkes WD
    Cancer; 2003 Feb; 97(3):527-36. PubMed ID: 12548593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
    Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
    Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.